KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non Operating Investment Income (2016 - 2017)

Supernus Pharmaceuticals (SUPN) has disclosed Non Operating Investment Income for 6 consecutive years, with $23000.0 as the latest value for Q2 2017.

  • Quarterly Non Operating Investment Income fell 81.3% to $23000.0 in Q2 2017 from the year-ago period, while the trailing twelve-month figure was $77000.0 through Dec 2017, down 82.81% year-over-year, with the annual reading at $76000.0 for FY2017, 83.04% down from the prior year.
  • Non Operating Investment Income for Q2 2017 was $23000.0 at Supernus Pharmaceuticals, down from $54000.0 in the prior quarter.
  • The five-year high for Non Operating Investment Income was $760000.0 in Q3 2014, with the low at -$8.6 million in Q2 2013.
  • Average Non Operating Investment Income over 5 years is -$545944.4, with a median of $100000.0 recorded in 2016.
  • The sharpest move saw Non Operating Investment Income crashed 5885.42% in 2013, then soared 12200.0% in 2016.
  • Over 5 years, Non Operating Investment Income stood at -$662000.0 in 2013, then surged by 204.83% to $694000.0 in 2014, then tumbled by 81.7% to $127000.0 in 2015, then dropped by 22.05% to $99000.0 in 2016, then plummeted by 76.77% to $23000.0 in 2017.
  • According to Business Quant data, Non Operating Investment Income over the past three periods came in at $23000.0, $54000.0, and $99000.0 for Q2 2017, Q1 2017, and Q4 2016 respectively.